Down 8%: What's Behind Teva's Massive Plunge?

Teva Pharmaceuticals (NYSE: TEVA  ) is not only one of the biggest generic drug manufacturers in the world but it also sells Copaxone, the branded blockbuster multiple sclerosis treatment. Despite this unique business model, the company has struggled to gain investor confidence over the last few years. It's facing a number of headwinds; the clock on Copaxone's market exclusivity is ticking fast; and new competitors in the multiple sclerosis space, such as Biogen's (NASDAQ: BIIB  ) recently launched drug Tecfidera, are another threat to this drug's sales.

Today, Teva's future is even more uncertain after its CEO announced his resignation. In the following video from The Motley Fool's health-care show, Market Checkup, analyst Max Macaluso discusses the details behind this move and what lies ahead for the company.

An incredible growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2706663, ~/Articles/ArticleHandler.aspx, 7/25/2014 5:32:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement